Bessemer Group Inc. Sells 5,010 Shares of SiBone $SIBN

Bessemer Group Inc. lessened its stake in SiBone (NASDAQ:SIBN) by 11.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,105 shares of the company’s stock after selling 5,010 shares during the period. Bessemer Group Inc. owned about 0.09% of SiBone worth $698,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Nuveen LLC bought a new position in SiBone during the first quarter worth about $18,605,000. First Light Asset Management LLC lifted its stake in SiBone by 41.8% during the first quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company’s stock worth $22,622,000 after purchasing an additional 475,426 shares during the period. American Century Companies Inc. lifted its stake in SiBone by 11.1% during the first quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock worth $37,072,000 after purchasing an additional 264,254 shares during the period. Victory Capital Management Inc. lifted its stake in SiBone by 55.0% during the first quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock worth $8,861,000 after purchasing an additional 224,190 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in SiBone by 765.3% during the first quarter. Russell Investments Group Ltd. now owns 201,758 shares of the company’s stock worth $2,831,000 after purchasing an additional 178,442 shares during the period. Institutional investors own 98.11% of the company’s stock.

Insider Activity

In other SiBone news, Director John Gordon Freund sold 12,132 shares of SiBone stock in a transaction on Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the sale, the director owned 91,767 shares of the company’s stock, valued at approximately $1,467,354.33. The trade was a 11.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Pisetsky sold 3,128 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $14.25, for a total transaction of $44,574.00. Following the completion of the transaction, the senior vice president directly owned 255,224 shares of the company’s stock, valued at $3,636,942. This trade represents a 1.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 44,141 shares of company stock worth $680,628. Corporate insiders own 4.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on SIBN. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an “overweight” rating in a research note on Monday, August 11th. Truist Financial cut their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

SiBone Price Performance

SIBN opened at $14.83 on Friday. The company has a fifty day moving average price of $15.34 and a two-hundred day moving average price of $16.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The firm has a market capitalization of $639.77 million, a PE ratio of -26.48 and a beta of 0.83.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone has set its FY 2025 guidance at EPS. As a group, analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.